Sales - Today Stories

Researchers have launched a clinical trial to develop a breath test, analysing molecules that could indicate the presence of cancer at an early stage. This is the first test of its kind to investigate multiple cancer types. A cancer breath test has huge potential to provide a non-invasive look into what’s happening in the body and could help to find cancer early, when treatment is more likely to be effective.  The Cancer Research UK Cambridge Centre is running the PAN Cancer trial for Early Detection of Cancer in Breath* in collaboration with Owlstone Medical** to test their Breath Biopsy® technology. Breath samples from people will be collected in the clinical trial to see if odorous molecules called volatile organic compounds (VOCs) can be detected. Profe…

Precision Medicine Group, Inc. (Precision) today announced it has acquired Stern Investor Relations, Inc. (Stern IR), a leading investor relations firm for entrepreneurial biotechnology and healthcare companies. With this acquisition, Precision significantly expands its capabilities to include a complete range of strategic communication services aimed at facilitating capital formation and enhancing client visibility and productive interactions with the financial community. Stern IR supports more than 70 companies in the entrepreneurial biotechnology and healthcare sectors, and its core competencies include creation of investor relations strategy aimed at lowering the cost of capital, positioning and messaging development, relationship building with the financial community, and seamless tac…

Kineta Immuno-Oncology, LLC (KIO), a subsidiary of Kineta, Inc., today announced that it has entered into a strategic research collaboration with Pfizer Inc. (NYSE: PFE) to develop RIG-I agonist immunotherapies for the treatment of cancer.  The research collaboration and license agreement grants to Pfizer the exclusive rights to KIO's RIG-I screening platform and related compounds and technologies.  The companies will collaborate to develop and test small molecule agonists that target RIG-I, an innate immunostimulatory pathway that can elicit immunogenic cell death (ICD) in tumors, providing both direct tumor cell killing and enhanced anti-tumor immune responses.  In preclinical models, Kineta's RIG-I agonists have demonstrated complete tumor regression and an increase…

Eli Lilly and Company (NYSE: LLY) today announced an agreement with Hydra Biosciences to acquire all assets related to  Hydra's pre-clinical program of TRPA1 antagonists, part of the Transient Receptor Potential (TRP) family of ion channels, that is currently being studied for the potential treatment of chronic pain syndromes. "At Lilly, we are committed to developing new treatment options for people struggling with chronic pain," said Mark Mintun, M.D., vice president of pain and neurodegeneration research at Lilly. "Through the acquisition of this promising pre-clinical program from Hydra, we will advance our understanding of the TRP pathway in pain signaling, and will seek to initiate clinical studies in the near term." "We are very excited to be transitioning this program into L…

Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, and SIRION Biotech GmbH today announced the entry into a license agreement, pursuant to which Orchard has licensed SIRION’s LentiBOOST™ technology to enhance manufacturing efficiency for certain of Orchard’s ex vivo autologous hematopoietic stem cell gene therapy drug candidates. “At Orchard Therapeutics, we are establishing manufacturing capabilities to deliver potentially transformative gene therapy products to rare disease patients around the globe. Optimization of lentiviral transduction through a technology such as LentiBOOST™, along with the build-out of our recentl…

BiomX Ltd., a microbiome company developing customized phage therapies, today announced that it has entered into a collaboration with Janssen Research & Development, LLC to utilize BiomX's XMarker microbiome-based biomarker discovery platform. The XMarker platform will be used to stratify responders and non-responders to inflammatory bowel disease (IBD) therapeutics. The collaboration was facilitated by Johnson & Johnson Innovation Limited. "The XMarker platform was created for BiomX's microbial target discovery, based on the advanced algorithms developed by our scientific founders and our internal computational team," stated Jonathan Solomon, CEO of BiomX. "Beyond target discovery, we believe that our microbiome analytics holds great promise for the development of a new clas…

Amgen (NASDAQ: AMGN) today announced a novel multi-year collaboration with Magellan Rx Management, the pharmacy benefit management division of Magellan Health, that will leverage each company's capabilities and resources to identify clinical gaps for some of the healthcare system's most difficult-to-treat diseases. Based on Amgen and Magellan's extensive expertise in complex areas of health and specialty populations, the initial projects will focus on improving patient outcomes for the treatment of osteoporosis and migraine. These projects mark Amgen's first value-based collaboration with a pharmacy benefit manager (PBM). "Amgen's collaboration with Magellan Rx demonstrates our commitment to cultivating deeper, more meaningful relationships with PBMs, moving beyond the typical transaction…

Orion Corporation and Novartis Pharma AG have agreed that Novartis will return the sales and distribution rights in certain European countries for Parkinson's disease drug Stalevo® to Orion.   The sales and distribution rights in certain European countries for the proprietary product Stalevo® (active pharmaceutical ingredients: levodopa, carbidopa, entacapone), which has been patented and developed by Orion for the treatment of Parkinson's disease, transfer from Novartis to Orion as of 3 December 2018.   Central nervous system (CNS) disorders are one of Orion's three core therapy areas, and, measured by net sales, Parkinson's disease drugs are Orion's largest family of pharmaceutical preparations. Stalevo has been on the market since 2003.   Orion has been responsible…

Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients’ unmet medical needs, is pleased to note the announcement today by Norgine that they have launched Feraccru® in the UK.  Feraccru® is a novel, effective and well tolerated treatment for Iron Deficiency in adults.  In September 2018, Shield licensed Feraccru® to Norgine B.V. in most European territories.   Carl Sterritt, Chief Executive Officer of Shield Therapeutics, added: “I am delighted that Norgine’s UK team is now starting to promote Feraccru® in the UK.  Since announcing the licence agreement in September 2018, we have been working closely with Norgine to transfer knowledge and responsibilities from Shield to them and…

Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, is pleased to announce that it has entered into agreement to acquire the metastatic skeletal cancer palliation drug, Metastron™, from GE Healthcare.   The agreement gives Q BioMed ownership of the brand, trademarks and market authorizations in 22 countries. In addition, all historical and current sales and distribution data related to those market authorisations will be assigned or transferred to Q BioMed to allow for as seamless a transition as possible in all markets.   Q BioMed CEO Denis Corin said of the deal, “This is a major deal for Q BioMed. Strategically, it affirms our belief in this drug as an effective and underutilized non-opioid therapy for the treatment of debilitating pain associated with skele…

The agreement will see the implementation of Elsevier's Order Sets and Care Planning solutions in all three Al Hammadi hospitals over the next five years Elsevier, the information analytics business specializing in science and health, today announced an agreement with Al Hammadi Company for Development and Investment (Al Hammadi) to implement Elsevier's Order Sets and Care Planning solutions in Al Hammadi hospitals across Saudi Arabia. Al Hammadi currently oversees three large hospitals in Riyadh, Saudi Arabia: Al Hammadi Hospital Al Olaya (300 beds), Al Hammadi Hospital Al Suwaidi (428 beds), and Al Hammadi Hospital Al Nuzha (600 beds). Implementation of Order Sets and Care Planning solutions marks an important step of digital transformation for the hospital. The Saudi Arabian governme…

Mazor Robotics Ltd. (TASE: MZOR; NASDAQGM: MZOR), a pioneer and a leader in the field of robotic guidance systems, today announced that at a Special General Meeting of Shareholders held earlier today, Mazor Robotics shareholders approved the previously announced definitive merger agreement with wholly-owned subsidiaries of Medtronic plc (NYSE: MDT). Approximately 53 percent of Mazor Robotics ordinary shares were represented in the meeting. Approximately 95 percent of the shares represented in the meeting which are neither held by a Medtronic affiliated party nor by a controlling shareholder of the Company or a shareholder with a personal interest in the merger proposal, were cast in favor of the merger. Upon completion of the transaction, Mazor Robotics shareholders will receive $58.50 p…

TIME has selected ACUVUE OASYS with Transitions Light Intelligent Technology as one of the 'Best Inventions of 2018,' in its annual round-up spotlighting groundbreaking innovations worldwide. The development of ACUVUE OASYS with Transitions has created and defined an entirely new category of contact lenses that provides wearers with vision correction and reduces blaring light*,i for all-day soothing vision.** The contact lenses – built for a modern and active lifestyle – help reduce exposure to bright light indoors and outdoors, including filtering blue light¨ and blocking UV rays that can impact eye comfort and vision.+‡ ii,iii,iv,v,vi "Receiving this prestigious designation for ACUVUE OASYS with Transitions alongside other game-changing inventions that are improving the way we live in…

Grünenthal announced today that it has acquired the US-based pharmaceutical company Averitas Pharma, thereby extending its commercial footprint to the United States. Averitas Pharma will be commercialising the pain patch Qutenza® (8 % capsaicin) for Grünenthal in the US. Grünenthal had only recently acquired the remaining global rights, including the US rights, for the product from Acorda Therapeutics. "I am proud to say that we are now establishing our own commercial presence in the world's biggest pharma market, the US, for the first time," says Gabriel Baertschi, Grünenthal's Chief Executive Officer. "This acquisition is another important milestone in executing our growth strategy and expanding our business across multiple pain related therapeutic categories and geographies. Averitas P…

Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Amneal Pharmaceuticals, Inc. (Amneal) with regard to Levothyroxine Sodium Tablets USP.  Under the agreement, Amneal will be Lannett's sole customer for Levothyroxine Sodium beginning December 1, 2018 through March 23, 2019, and will re-sell the products to its customers.  Lannett will receive an upfront payment of $50 million, other terms of the transaction were not disclosed. As previously announced, Lannett's distribution agreement with Jerome Stevens Pharmaceuticals (JSP), which includes Levothyroxine Sodium Tablets USP, expires on March 23, 2019 and will not be renewed. "This agreement benefits all parties, including and importantly patients and customers who can be assured of a def…

Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ: MYL) ("Mylan") today announced that the U.S. Food and Drug Administration (FDA) has approved the  New Drug Application (NDA) for YUPELRITM (revefenacin) inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI, a long-acting muscarinic antagonist (LAMA), is the first and only once-daily, nebulized bronchodilator approved for the treatment of COPD in the US. The companies expect YUPELRI to be available to COPD patients in the US before the end of the year. COPD is the third leading cause of death and the fourth leading cause of hospital readmissions in the US, affecting approximately 16 million Americans. "Long-acting muscarinic ant…

-        Upfront payment of US$15m -        Up to US$80m of development milestone payments -        Mid teen percentage profit share arrangement for each portfolio product Chippenham, UK – 08 November 2018: Vectura Group plc (LSE: VEC) ("Vectura", "the Group"), today announces signing an agreement with Hikma Pharmaceuticals PLC ("Hikma") for the global development and commercialisation of generic versions of GSK’s Ellipta® portfolio, utilising Vectura’s proprietary Open-Inhale-Close dry powder inhaler device. Following interactions with US FDA, the Open-Inhale-Close dry powder inhaler device has the potential to be developed as an AB-rated substitutable drug-device combination for g…

American Healthcare Investors and Griffin Capital Company, LLC, the co-sponsors of Griffin-American Healthcare REIT IV, Inc., announced today that the REIT completed the acquisition of 13 healthcare buildings in five states for an aggregate contract purchase price of approximately $178.4 million during the third quarter of 2018. The acquisitions were comprised of three medical office buildings, two senior housing facilities and eight skilled nursing facilities. "We continue to acquire accretively for the quickly growing portfolio of Griffin-American Healthcare REIT IV," said Stefan Oh, executive vice president of acquisitions for American Healthcare Investors and Griffin-American Healthcare REIT IV. "Including acquisitions completed during and after the close of the third quarter, our por…

WELL Health Technologies Corp. (TSX.V: WELL) (the "Company or "WELL"), a company focused on consolidating and modernizing clinical and digital assets within the primary healthcare sector, is pleased to announce that it has entered into a subscription agreement with Circle Medical Inc. ("Circle Medical") to invest $200,000 USD in the Silicon Valley based digital health company's latest round of financing. "We are pleased to become shareholders of Circle Medical a company that has been successful in developing technology applications that have contributed to a more digital and convenient patient experience," said Hamed Shahbazi, Chairman and CEO of WELL Health Technologies.  "We look forward to considering various ways we can unlock value together as both companies evolve and augment c…

Medela LLC announced today that Apria Healthcare, one of the nation's largest providers of home healthcare and equipment services, will begin distributing Medela's negative pressure wound therapy (NPWT) product line on a national basis. Under the terms of the agreement, Apria will expand its wound care portfolio to include the full line of Medela's negative pressure wound therapy products, including the Invia® NPWT System with FitPad.  Apria will offer the Medela products through its more than 300 local branch offices and its nearly 1,900 commercial payers and preferred provider arrangements with integrated health systems across the country. "I am excited about bringing Apria and Medela together," said Kevin Ackermann, vice president of healthcare for Medela USA.  "By offering…